News
The decision follows the initial approval granted in September 2023, which covered patients aged five years and above.
For patients with severe elevations in low-density lipoprotein (LDL) cholesterol (≥190 mg/dL) and a combination of clinical signs and family history to suggest familial hypercholesterolemia (FH ...
Heart disease is often seen as a problem that only affects older adults, but more and more young people are being diagnosed ...
Do you have high cholesterol? You're not alone — millions of adults in the United States face this common but serious issue. High cholesterol increases the risk of heart disease, ...
In recent study, 23 percent of NHANES primary prevention cohort currently using lipid-lowering therapies versus 47 percent eligible under U.S. guidelines.
6d
GlobalData on MSNArrowhead doses first patient in Phase III trial of zodasiran for HoFH treatmentThe placebo-controlled study is aimed at assessing the safety and efficacy of zodasiran in adults and adolescents with HoFH.
While your genes certainly do play a part in shaping your predisposition to high cholesterol, they are not the sole or ...
3d
Live Science on MSNExperimental treatment for high cholesterol edits DNA in the body to reduce LDLAn experimental treatment called VERVE-102 lowers the amount of "bad" cholesterol in the blood of people with specific ...
Studies suggest that artichoke extract can help lower cholesterol and blood pressure, reduce liver inflammation, and aid with ...
Arrowhead Pharma Kicks Off Phase III Trial for Zodasiran in Homozygous Familial Hypercholesterolemia
The firm is hoping to show that the RNAi drug can treat HoFH by reducing production of ANGPTL3, which regulates lipid and lipoprotein metabolism.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results